IMMUNOLOGICAL PROFILE LINKED CLINICAL APPEARANCE AND OUTCOME IN ADVANCED STAGE MANTLE CELL LYMPHOMA

被引：0
|
作者：
Todorovic, M. [1 ]
Mihaljevic, B. [1 ]
Balint, B. [2 ]
Kraguljac, N. [1 ]
Andjelic, B. [1 ]
Perunicic, B. [1 ]
Markovic, O. [1 ]
Petrovic, M. [1 ]
机构：
[1] Clin Ctr Serbia, Belgrade, Serbia
[2] Inst Med Res, Belgrade, Serbia
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2009年 / 94卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1694
引用
收藏
页码：649 / 650
页数：2
相关论文
共 50 条
  • [21] Mantle cell lymphoma: Correlation of clinical outcome and biologic features with three histologic variants
    Majlis, A
    Pugh, WC
    Rodriguez, MA
    Benedict, WF
    Cabanillas, F
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (04) : 1664 - 1671
  • [22] Prognosis and outcome of stem cell transplantation for mantle cell lymphoma
    Cheminant, Morgane
    Robinson, Stephen
    Ribrag, Vincent
    Le Gouill, Steven
    Suarez, Felipe
    Delarue, Richard
    Hermine, Olivier
    EXPERT REVIEW OF HEMATOLOGY, 2015, 8 (04) : 493 - 504
  • [23] Limited-stage mantle-cell lymphoma
    Leitch, HA
    Gascoyne, RD
    Chhanabhai, M
    Voss, NJ
    Klasa, R
    Connors, JM
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1555 - 1561
  • [24] Autologous stem cell transplantation and Rituximab independently prolong response duration in advanced stage mantle cell lymphoma
    Hoster, E.
    Metzner, B.
    Pfreundschuh, M.
    Truemper, L.
    Hallek, M.
    Woermann, B.
    Duehrsen, U.
    Gisselbracht, C.
    Kluin-Nelemans, J. C.
    Van Hoof, A.
    Unterhalt, M.
    Hiddemann, W.
    Dreyling, M.
    ONKOLOGIE, 2010, 33 : 202 - 202
  • [25] Topoisomerase IIα expression in mantle cell lymphoma: a marker of cell proliferation and a prognostic factor for clinical outcome
    C Schrader
    P Meusers
    G Brittinger
    A Teymoortash
    J-U Siebmann
    D Janssen
    R Parwaresch
    M Tiemann
    Leukemia, 2004, 18 : 1200 - 1206
  • [26] Topoisomerase IIα expression in mantle cell lymphoma:: a marker of cell proliferation and a prognostic factor for clinical outcome
    Schrader, C
    Meusers, P
    Brittinger, G
    Teymoortash, A
    Siebmann, JU
    Janssen, D
    Parwaresch, R
    Tiemann, M
    LEUKEMIA, 2004, 18 (07) : 1200 - 1206
  • [27] Clinical management of mantle cell lymphoma in the elderly
    Smolewski, Piotr
    Rydygier, Dominika
    Robak, Tadeusz
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1893 - 1905
  • [28] Clinical Management Updates in Mantle Cell Lymphoma
    Chen, Robert
    Sanchez, James
    Rosen, Steven T.
    ONCOLOGY-NEW YORK, 2016, 30 (04): : 353 - 360
  • [29] Clinical features and management of mantle cell lymphoma
    Grifi, Fatiha
    Bougherira, Soraya
    Djenouni, Amel
    CANCER IMMUNOLOGY RESEARCH, 2019, 7 (02)
  • [30] TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage
    Hua-Jie Dong
    Li-Tao Zhou
    Cheng Fang
    Lei Fan
    Dan-Xia Zhu
    Yin-Hua Wang
    Jian-Yong Li
    Wei Xu
    Medical Oncology, 2012, 29 : 2166 - 2173
12345